EAI045
CAS No. 1942114-09-1
EAI045 ( EAI045 | EAI-045 | EAI 045 )
产品货号. M17407 CAS No. 1942114-09-1
EAI045 是一种变构抑制剂,针对耐药 EGFR 突变体,但避开野生型受体。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥292 | 有现货 |
|
| 10MG | ¥437 | 有现货 |
|
| 25MG | ¥680 | 有现货 |
|
| 50MG | ¥1021 | 有现货 |
|
| 100MG | ¥1677 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称EAI045
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述EAI045 是一种变构抑制剂,针对耐药 EGFR 突变体,但避开野生型受体。
-
产品描述EAI045 ia a potent and selective EGFR inhbitor. EAI045 targets selected drug-resistant EGFR mutants but spares the wild-type receptor. EAI045 inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays.
-
体外实验EAI045 potently inhibits EGFR Y1173 phosphorylation in H1975 cells (EC50=2 nM), but not in HaCaT cells. EAI045 is an inhibitor of the L858R/T790M mutant with 1000-fold selectivity versus wild type EGFR at 1 mM ATP. Profiling of EAI045 against a panel of 250 protein kinases reveals exquisite selectivity; no other kinases are inhibited by more than 20% at 1 μM EAI045. EAI045 has high potency and selectivity for L858R/T790M mutation. In L858R/T790M-mutant NSCLC cell line H1975 cells, EAI045 decreases but does not completely abolish the EGFR autophosphorylation. In stably transfected NIH-3T3 cells harboring the L858R/T790M EGFR mutant, EAI045 shows the same activity. In L858R-mutant H3255 cells, EAI045 exhibits moderate activity. In the HaCaT cells, a keratinocyte cell line with wild-type EGFR, EAI045 does not show any activity of inhibiting EGFR phosphorylation. It confirms the selectivity of EAI045 for mutant EGFR.
-
体内实验In a genetically engineered mouse model of L858R/T790Mmutant-driven lung cancer , remarkable tumor regression is observed in L858R/T790M-mutant mice treated with the combination of EAI045 and cetuximab. No response is seen in those mice treated with EAI045 alone. The same effect is seen in both L858R/T790M/C797S- engineered Ba/F3 cells and in mice carrying the L858R/T790M/C797S tumor xenografts. These assays clearly show that EAI045 can overcome resistance from acquired T790M and C797S mutations.
-
同义词EAI045 | EAI-045 | EAI 045
-
通路MAPK/ERK Signaling
-
靶点p38 MAPK
-
受体EGFR mutants
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1942114-09-1
-
分子量383.4
-
分子式C19H14FN3O3S
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 28 mg/mL; 73.03 mM
-
SMILESc1ccc2c(c1)CN(C2=O)C(C(=O)Nc1sccn1)c1cc(ccc1O)F
-
化学全称2-(5-fluoro-2-hydroxyphenyl)-2-(3-oxo-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Jia Y et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016 May 25;534(7605):129-32.
产品手册
关联产品
-
Maohuoside A
毛霍苷 A 通过 BMP 和 MAPK 信号通路促进大鼠间充质干细胞的成骨。
-
MAPK13-IN-1
MPAK13-IN-1 是 MAPK13 (p38δ) 的一个抑制剂,其 IC50 值为 620 nM。
-
p38 MAP Kinase Inhib...
p38 MAP Kinase Inhibitor Ⅵ (compound c32) 是 p38 MAPK 抑制剂,抑制率达到 24%。
021-51111890
购物车()
sales@molnova.cn

